Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | BCDIN3D | Q7Z5W3 | 4/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | OGG1 | O15527 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
| ▸ | TGM2 | P21980 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1419878 | 0.83 | IDO1 (0.41) | GBA1IDO1TDO2BCDIN3DMAOA | |
| SCHEMBL30689582 | 0.80 | TAAR1 (0.47) | GBA1IDO1TDO2BCDIN3DMAOA | |
| SCHEMBL7752784 | 0.80 | IDO1 (0.36) | GBA1IDO1TDO2OGG1TGM2 | |
| SCHEMBL3455734 | 0.80 | IDO1 (0.36) | GBA1IDO1TDO2OGG1TGM2 | |
| SCHEMBL30414866 | 0.80 | IDO1 (0.39) | GBA1IDO1TDO2 | |
| SCHEMBL25264955 | 0.80 | IDO1 (0.39) | GBA1IDO1TDO2 | |
| SCHEMBL25189449 | 0.80 | IDO1 (0.39) | GBA1IDO1TDO2 | |
| SCHEMBL3455735 | 0.80 | IDO1 (0.36) | GBA1IDO1TDO2OGG1TGM2 | |
| SCHEMBL16564871 | 0.79 | DPP4 (0.39) | MAOATGM2 | |
| SCHEMBL8050506 | 0.78 | CYP2C19 (0.44) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297112-B1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | CCR1, CCR3, CCR4 | GBA1 2238/4885IDO1 187/4885TDO2 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.